644 THE IMPACT OF ANDROGEN LEVELS ON THE RISK OF HIGH GRADE PROSTATE CANCER: EVALUATING THE FREE TO TOTAL TESTOSTERONE RATIO

2011 ◽  
Vol 10 (2) ◽  
pp. 208
Author(s):  
S. Albisinni ◽  
C. De Nunzio ◽  
A. Tubaro ◽  
L.L. Banez ◽  
S.J. Freedland
Keyword(s):  
Prostate Cancer ◽  
Total Testosterone ◽  
High Grade ◽  
The Impact ◽  
Androgen Levels

2330 THE IMPACT OF ANDROGEN LEVELS ON THE RISK OF HIGH GRADE PROSTATE CANCER: EVALUATING PERCENT FREE TESTOSTERONE

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Simone Albisinni ◽  
Cosimo De Nunzio ◽  
Andrea Tubaro ◽  
Lionel L. Banez ◽  
Stephen J. Freedland
Keyword(s):  
Prostate Cancer ◽  
Free Testosterone ◽  
High Grade ◽  
The Impact ◽  
Androgen Levels

scholarly journals Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Paula Kappler ◽  
Michael A. Morgan ◽  
Philipp Ivanyi ◽  
Stefan J. Brunotte ◽  
Arnold Ganser ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Cox Regression ◽  
Specific Antigen ◽  
Progression Free Survival ◽  
Serum Levels ◽  
Biologically Active ◽  
Free Form ◽  
Total Testosterone ◽  
The Impact

AbstractTo date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to < 0.18 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified requirement of non-narcotics, PSAR, complete FT suppression and FT nadir values < 0.18 pg/mL as independent parameters for PFS. Prior androgen-receptor targeted therapy (ART), soft tissue metastasis and complete FT suppression were independent prognostic factors for OS. FT was not predictive for treatment outcome in mPC patients with a history of ART.

125 The Relationship Between PSA and Total Testosterone Levels in Men with Low, Intermediate and High Grade Prostate Cancer

2019 ◽  
Vol 16 (4) ◽  
pp. S64-S65
Author(s):  
H.L. Bernie ◽  
B. Nascimento ◽  
E. Miranda ◽  
A. Tin ◽  
N. Benfante ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Total Testosterone ◽  
High Grade ◽  
Testosterone Levels ◽  
The Relationship

scholarly journals Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients

2016 ◽  
Vol 10 (2) ◽  
pp. 72-80 ◽  
Author(s):  
Antonio B. Porcaro ◽  
Nicolò De Luyk ◽  
Paolo Corsi ◽  
Marco Sebben ◽  
Alessandro Tafuri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Plasma Levels ◽  
Specific Antigen ◽  
Continuous Variable ◽  
Categorical Variables ◽  
Total Testosterone ◽  
High Grade ◽  
Entire Cohort ◽  
Replacement Treatment ◽  
Lh Releasing Hormone

Objectives: To investigate the associations, if any, between preoperative plasma levels of total testosterone (TT) and pathology Gleason score (pGS) in a contemporary cohort of prostate cancer (PCa) patients. Materials and Methods: Between November 2014 and June 2015, plasma levels of TT were measured in 142 patients who underwent radical prostatectomy. Exclusion criteria were as follows: 5α-reductase inhibitors, LH-releasing hormone analogues, or testosterone replacement treatment. The entire cohort, assessed by continuous and categorical variables, was classified into two groups according to the pGS that included low-intermediate (pGS 6-7) and high grade (pGS > 7) cases. TT was evaluated as a continuous variable. Results: The cohort included 128 cases. High grade PCa was detected in 28 (21.8%) patients. Median plasma levels of both TT and prostate specific antigen (PSA) were significantly higher in these cases. In the clinical multivariate model, independent and positive predictors of pGS > 7 were TT (p = 0.041; OR = 1.004), PSA (p = 0.006; OR = 1.191), and bGS > 6 (p = 0.004; OR = 5.0); that is, a single unit increase in TT plasma levels increases the odds of having high grade PCa by 4%. Conclusion: In a contemporary cohort of patients, preoperative plasma levels of TT directly and independently associated with high grade PCa. High baseline plasma levels of TT might have clinical applications for managing PCa. New and well designed prospective studies dealing with this subject are required.

scholarly journals Low serum testosterone is a predictor of high-grade disease in patients with prostate cancer

2017 ◽  
Vol 63 (8) ◽  
pp. 704-710 ◽  
Author(s):  
George A. M. Lins de Albuquerque ◽  
Giuliano B. Guglielmetti ◽  
João Arthur B. A. Barbosa ◽  
José Pontes Jr. ◽  
Arnaldo J. C. Fazoli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Black Men ◽  
Multivariate Analyses ◽  
White Men ◽  
Serum Testosterone ◽  
Demographic Characteristics ◽  
Total Testosterone ◽  
High Grade ◽  
Independent Risk Factors ◽  
Low Serum

Summary Objective: To evaluate the relation between serum total testosterone (TT) and prostate cancer (PCa) grade and the effect of race and demographic characteristics on such association. Method: We analyzed 695 patients undergoing radical prostatectomy (RP), of whom 423 had serum TT collected. Patients were classified as having hypogonadism or eugonadism based on two thresholds of testosterone: threshold 1 (300 ng/dL) and threshold 2 (250 ng/dL). We evaluated the relation between TT levels and a Gleason score (GS) ≥ 7 in RP specimens. Outcomes were evaluated using univariate and multivariate analyses, accounting for race and other demographic predictors. Results: Out of 423 patients, 37.8% had hypogonadism based on the threshold 1 and 23.9% based on the threshold 2. Patients with hypogonadism, in both thresholds, had a higher chance of GS ≥ 7 (OR 1.79, p=0.02 and OR 2.08, p=0.012, respectively). In the multivariate analysis, adjusted for age, TT, body mass index (BMI) and race, low TT (p=0.023) and age (p=0.002) were found to be independent risk factors for GS ≥ 7. Among Black individuals, low serum TT was a stronger predictor of high-grade disease compared to White men (p=0.02). Conclusion: Hypogonadism is independently associated to higher GS in localized PCa. The effect of this association is significantly more pronounced among Black men and could partly explain aggressive characteristics of PCa found in this race.

scholarly journals Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer

2016 ◽  
Vol 10 (4) ◽  
pp. 174-181
Author(s):  
Antonio B. Porcaro ◽  
Salvatore Siracusano ◽  
Nicolò de Luyk ◽  
Paolo Corsi ◽  
Marco Sebben ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Follicle Stimulating Hormone ◽  
Specific Antigen ◽  
Localized Prostate Cancer ◽  
Total Testosterone ◽  
High Grade ◽  
The Third ◽  
Simultaneous Measurements ◽  
Tumor Load ◽  
Stimulating Hormone

Objectives: To evaluate the potential relations of simultaneous measurements of basal levels of follicle stimulating hormone (FSH) and total testosterone (TT) in clinically localized prostate cancer (PCa). Materials and Methods: The study included 126 patients who had simultaneous measurements of prostate specific antigen (PSA), FSH, and TT before undergoing radical prostatectomy for clinically localized PCa. Correlations and independent associations between clinical and pathological factors were investigated by statistical methods. Results: The tumor volume (TV) was directly correlated to PSA and TT which was inversely related to FSH. Moreover, it was independently associated with both PSA and TT. In a multivariate linear regression model, FSH and TV were simultaneous independent factors associated with TT, and the association was inverse in the former and direct in the latter. In the patient population, the subset with FSH levels above the third quartile was related to lower median levels of TT that were associated with high grade cancer showing a lower TV. In localized PCa, basal levels of TT were associated with tumor parameters and inversely related to FSH levels, and the subset FSH levels above the third quartile were related to lower TT levels that were associated with high grade cancers showing a lower tumor load. Conclusion: Preoperative TT was associated with tumor parameters and inversely related to FSH levels. Patient with increased FSH levels was related to lower levels of TT, which was associated with high grade cancer.

Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC).

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 145-145
Author(s):  
Stefan Brunotte ◽  
Philipp Ivanyi ◽  
Paula Kappler ◽  
Michael A. Morgan ◽  
Christoph W. Reuter
Keyword(s):  
Prostate Cancer ◽  
Detection Limit ◽  
Lung Metastases ◽  
Objective Response ◽  
Specific Antigen ◽  
Serum Levels ◽  
Total Testosterone ◽  
Castration Resistant Prostate Cancer ◽  
The Impact

145 Background: Carboplatin plus docetaxel (CD) may be effective in mDRPC. Platinum(II)-complexes interfere with steroid biosynthesis and thus lower testosterone levels . In this study, the impact of CD on free and total testosterone (fT, TT) serum levels and the prognostic role of fT and TT were analyzed in mDRPC patients. Methods: Docetaxel failure/resistance was defined according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Treatment consisted of at least 2 cycles of carboplatin AUC5 iv for 30 min on day 1 every 4 weeks (q4w), docetaxel (35 mg/m2) iv for one hour on days 1, 8, (15) plus prednisone 2x5 mg/day orally after receiving informed consent until disease progression or occurrence of intolerable adverse effects. Efficacy measures were done following PCWG2 recommendations. Results: Of the 118 pts. treated since February 2005, 95.8% had bone, 47.5% lymph node, 28.0% liver and 20.3% lung metastases. Median follow-up time was 14.4 months at the time of the current analysis. The objective response rate (ORR) was 46.4% in the 69 pts. with measureable disease (58.5%). Response of prostate-specific antigen (PSAR ≥ 50%) was observed in 56 (47.9%) patients. Median progression free survival (PFS) was 7.6 months (CI 95% 6.0, 9.1) and median overall survival (OS) was 15.7 months (CI 95% 12.2, 19.2). The most common reversible grade 3/4 toxicity was leukopenia/ neutropenia (36.4/28.8%). Median FT serum levels were 0.35 pg/mL before and < 0.18 pg/mL during CD treatment (nadir levels, p < 0.001; detection limit < 0.18 pg/mL). In multivariate analyses, LDH > 2xULN, PSAR≥50% and FT nadir levels below the detection limit ( < 0.18 pg/mL) during CD treatment were associated with longer PFS (p < 0.05). Conclusions: These data suggest that CD may be an important salvage treatment option for mDRPC patients by inhibition of the testosterone biosynthesis.

Impact of 5-ALPHA reductase inhibitor use on prostate cancer risk at the time of urology referral.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 226-226
Author(s):  
James T Kearns ◽  
Justin T. Matulay ◽  
William E. Anderson ◽  
Timothy C. Hetherington ◽  
Claud Grigg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Demographic Data ◽  
Laboratory Data ◽  
Prostate Cancer Risk ◽  
Collaborative Group ◽  
Ambulatory Setting ◽  
High Grade ◽  
Reductase Inhibitors ◽  
Psa Testing ◽  
The Impact

226 Background: 5-alpha reductase inhibitors (5-ARIs) are commonly used medications for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. One of the consequences of 5-ARI use is a 50% drop in serum PSA without a concomitant reduction in prostate cancer (PCa) risk. Previous work has suggested that 5-ARI use is associated with worse PCa-specific outcomes. The objective of this study was to evaluate the impact of 5-ARI use on patients’ PCa risk at the time of referral from primary care to urology. Methods: This retrospective cohort study included all men ≥ 40 years who had a PSA resulted between 2018-2019 and were seen in an ambulatory setting. PSA testing was determined through laboratory data in the electronic health record (EHR). Clinical and demographic data were collected for all men. 5-ARI use was determined through orders in the EHR. Men were assigned PCa risk according to both the Prostate Biopsy Collaborative Group (PBCG) and Prostate Cancer Prevention Trial (PCPT) risk calculators. PSA values were doubled for 5-ARI users prior to calculating risk. Referral to urology for PCa risk was determined using the narrative reason for referral associated with the referral order. Results: Between 2018-2019, 91,368 men had a PSA test, including 2,939 5-ARI users, and 88,429 non-users. Uncorrected median PSA and the proportion of men referred to urology for PCa risk were similar between the two groups (p = 0.60 and p = 0.17, respectively). Of men referred to urology for PCa risk, 5-ARI users had similar uncorrected PSA to non-users (p=0.86) but higher risk for high grade PCa once PSA correction was performed, median (IQR) 48% (24%) vs 28% (18%) using the PBCG and 21% (17%) vs 10% (10%) using the PCPT (p < 0.01 for both) (Table). Conclusions: Men taking 5-ARIs have significantly higher risk for high-grade PCa at time of referral to urology than non-users in this cohort. As the unadjusted PSA at referral to urology for PCa risk was the same between 5-ARI users and non-users, this indicates that the effect of 5-ARI use on serum PSA levels is not routinely accounted for when assessing PCa risk. Further study on interventions to account for 5-ARI use when screening for PCa are warranted. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document